BIOSIMILAR MEDICINES:
INFORMATION FOR SPECIALISTS

RACP

This one hour activity is an introduction to biosimilar medicines in Australia. It will briefly look at the development and approval process of biosimilar medicines, as well as provide insights into the clinical experience and practical aspects of biosimilar medicines in practice.

Learning outcomes

This activity addresses the following learning outcomes using a combination of reading and active listening to video content.

Upon completion of this activity, participants will be able to:

EXPERTISE
  • explain how biosimilar medicines contribute to the sustainability of the Australian healthcare system
  • outline the clinical development and regulatory processes required prior to approval of biosimilar medicines
PATIENT CARE
  • explain to patients what a biosimilar medicine is, why it is different to a generic medicine, and their therapeutic equivalence to the reference biological product
  • manage patient concerns and queries surrounding biosimilar medicines
PRACTICE
  • define the criteria that must be met in order to substitute a PBS-subsidised reference biological for a biosimilar medicine.
RACP

This education has been designed for the RACP CPD Program for the 2023-25 triennium. Upon completion of this activity you may claim 1 hour of Category 1 Educational Activity learning in the RACP’s MyCPD program.

Other healthcare professionals can still enrol and complete this course.
You will receive a certificate upon completion.

START LEARNING

If you do not already have an account with Arterial Education, you will be required to create one. This verifies that you are a healthcare professional and allows you to log your learning activities.